Abstract 359P
Background
In particular, cancer patients with minor children encounter various problems, including family, parenting, employment, and economic burdens. This study aimed to examine the economic burden among cancer patients with minor children.
Methods
This was a sub-analysis of a cross-sectional web-based survey. Cancer patients with minor children were recruited from an online community and asked to answer a questionnaire.The proportion of subjects experiencing economic burden, and factors associated with economic burden were analyzed.
Results
A total of 368 subjects were eligible [19% male, mean age (SD): 43.0 years (5.8)]. The most common primary cancer site was breast (34%), followed by the colorectal region (12%), and gynecological organs (11%). Among the subjects, 127 (34%) experiencedeconomic burden. Univariate analyses showed that advanced stage (38% in subjects experiencing economic burden vs. 22% in subjects not experiencingeconomic burden, p = 0.002), presence of metastases (51% vs. 35%, p = 0.004), cancer recurrence (24% vs. 14%, p = 0.032), using anti-tumor drugs (47% vs. 33%, p = 0.010), having a full-time job (24% vs. 48%, p < 0.001), change of work situation (76% vs. 44%, p < 0.001), and decrease of income (76% vs. 38%, p < 0.001) were associated with patients experiencingeconomic burden.
Conclusions
The present study showed that advanced stage, anti-tumor treatment, and work situation were associated with economic burden among cancer patients with minor children.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center.
Funding
Takeda Science Foundation.
Disclosure
K. Kosugi: Honoraria (self): Mundipharma. D. Fujisawa: Honoraria (self): Pfeizer, Mochida, Tanabe-Mitsubishi, Shionogi, Meiji Pharma, MSD. T. Kawaguchi: Honoraria (self): Chugai. K. Izumi: Full / Part-time employment: Medilead Inc. J. Takehana: Full / Part-time employment: Medilead Inc. Y. Matsumoto: Honoraria (self): Kyowa Kirin; Honoraria (self): Shionogi; Honoraria (self): Terumo; Honoraria (self): Meiji Seika Pharma; Honoraria (self): Hisamitsu Pharmaceutical; Honoraria (self): Eisai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self): Mundipharma; Honoraria (self): Daiichi-Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract